These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
NOTICE OF VIRTUAL ANNUAL MEETING OF STOCKHOLDERS
|
YOUR VOTE IS IMPORTANT
|
|||||||||||||||||
You are cordially invited to attend the virtual annual meeting via the following website: http://www.virtualshareholdermeeting.com/SAIC2021. Whether or not you expect to virtually attend, please submit your proxy or voting instructions:
|
|||||||||||||||||
![]() |
By Internet
|
![]() |
By Telephone
|
![]() |
By Mail
|
||||||||||||
For specific instructions regarding how to vote, please refer to the questions and answers beginning on page 6 of this Proxy Statement or the instructions on the proxy and voting instruction card. Submitting a proxy or voting instructions will not prevent you from attending the virtual annual meeting and voting at the meeting if you so desire but will help us secure a quorum and reduce the expense of additional proxy solicitation.
|
SUMMARY INFORMATION |
•
Time and Date:
|
9:00 a.m. (ET) on June 2, 2021 | ||||
•
Website:
|
http://www.virtualshareholdermeeting.com/SAIC2021 | ||||
•
Record Date:
|
April 6, 2021 | ||||
•
Voting:
|
Stockholders as of the record date are entitled to vote. | ||||
•
Attendance:
|
All stockholders and their duly appointed proxies may attend the virtual meeting. |
Agenda Item
|
Board Recommendation
|
Page
|
||||||
Proposal 1: Election of ten directors.
|
FOR EACH NOMINEE
|
|||||||
Proposal 2: Approval of a non-binding, advisory vote to approve the compensation of our named executive officers ("Say-on-Pay").
|
FOR
|
|||||||
Proposal 3: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 28, 2022. | FOR |
Nominee
|
Age | Director Since |
Principal Occupation
|
Committees
|
||||||||||
Robert A. Bedingfield
|
72 | 2013 |
Former Global Coordinating Partner at Ernst & Young LLP
|
•
Audit (Chair)
•
Compensation
|
||||||||||
Carol A. Goode | 67 | 2019 | Private Consultant and Former Chief Human Resources Officer for Brocade Communication Systems |
•
Compensation
•
Nominating
|
||||||||||
Garth N. Graham
(1)
|
46 | 2021 | Director and Global Head of Healthcare for YouTube, LLC |
•
Compensation
|
||||||||||
John J. Hamre | 70 | 2013 | Chief Executive Officer and President of the Center for Strategic & International Studies; former U.S. Deputy Secretary of Defense and Under Secretary of Defense (Comptroller) |
•
Nominating
•
Risk Oversight (Chair)
|
||||||||||
Yvette M. Kanouff | 55 | 2019 | Partner and Chief Technology Officer for JC2 Ventures |
•
Audit
•
Risk Oversight
|
||||||||||
Nazzic S. Keene | 60 | 2019 | Chief Executive Officer of SAIC |
•
Risk Oversight
|
||||||||||
Timothy J. Mayopoulos | 62 | 2015 | President of Blend Labs, Inc.; former President & Chief Executive Officer at the Federal National Mortgage Association (Fannie Mae) |
•
Audit
•
Nominating (Chair)
|
||||||||||
Katharina G. McFarland | 61 | 2019 |
Private Consultant and former Assistant Secretary of Defense (Acquisition), Dept. of the Army
|
•
Nominating
•
Risk Oversight
|
||||||||||
Donna S. Morea | 66 | 2013 | Chair of SAIC's Board; former President of U.S., Europe, and Asia for CGI Group |
•
Nominating
•
Risk Oversight
|
||||||||||
Steven R. Shane | 63 | 2013 | Former partner at Accenture PLC |
•
Audit
•
Compensation (Chair)
|
1 | saic.com
|
SUMMARY INFORMATION |
Science Application International Corporation | ||||||||
2021 Proxy Statement | 2
|
TABLE OF CONTENTS |
INFORMATION ABOUT THE ANNUAL MEETING OF STOCKHOLDERS
|
||||||||
4 | ||||||||
PROPOSAL 1 - ELECTION OF DIRECTORS | ||||||||
Majority Voting Standard in Uncontested Director Elections
|
||||||||
Recommendation of the Board of Directors | ||||||||
Nominees for Election to the Board of Directors
|
||||||||
|
4 | |||||||
CORPORATE GOVERNANCE | ||||||||
Corporate Governance Guidelines
|
||||||||
Proxy Access
|
||||||||
Code of Conduct
|
||||||||
Director Independence
|
||||||||
Criteria for Board Membership
|
||||||||
Board Leadership Structure
|
||||||||
The Board’s Role in Risk Oversight
|
||||||||
Board of Directors Meetings and Committees
|
||||||||
Board of Directors Compensation
|
||||||||
Related Party Transactions
|
||||||||
Communication with the Board of Directors
|
||||||||
|
||||||||
PROPOSAL 2 - ADVISORY (NON-BINDING) VOTE ON EXECUTIVE COMPENSATION | ||||||||
Vote Required
|
||||||||
Recommendation of the Board
|
||||||||
COMPENSATION DISCUSSION AND ANALYSIS
|
||||||||
Human Resources and Compensation Committee Report
|
||||||||
|
4 | |||||||
EXECUTIVE COMPENSATION
|
||||||||
Summary Compensation Table | ||||||||
Grants of Plan-Based Awards | ||||||||
Outstanding Equity Awards at Fiscal Year-End
|
||||||||
Options Exercised and Stock Vested
|
||||||||
Nonqualified Deferred Compensation
|
||||||||
Potential Payments upon Termination or a Change in Control
|
||||||||
CEO Pay Ratio
|
||||||||
PROPOSAL 3 - RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | ||||||||
Vote Required
|
||||||||
Recommendation of the Board
|
||||||||
AUDIT MATTERS
|
||||||||
Audit Committee Report
|
||||||||
Independent Registered Public Accounting Firm
|
3 | saic.com
|
TABLE OF CONTENTS |
Audit and Non-Audit Fees
|
||||||||
|
4 | |||||||
OTHER INFORMATION
|
||||||||
Stock Ownership of Certain Beneficial Owners
|
||||||||
Stock Ownership of Directors and Officers
|
||||||||
Delinquent Section 16(a) Reports
|
||||||||
Stockholder Proposals and Director Nominations for the 2022 Annual Meeting | ||||||||
Annual Report on Form 10-K
|
||||||||
Appendix to Proxy Statement
|
Science Application International Corporation | ||||||||
2021 Proxy Statement | 4
|
INFORMATION ABOUT THE ANNUAL MEETING OF STOCKHOLDERS |
5 | saic.com
|
INFORMATION ABOUT THE ANNUAL MEETING OF STOCKHOLDERS |
![]() |
![]() |
||||
By Internet | By Telephone | ||||
You may submit a proxy or voting instructions over the Internet by going to
www.proxyvote.com
or by scanning the QR code on your proxy and voting instruction card with a smart phone and following the instructions.
|
You may submit a proxy or voting instructions by calling 1-800-690-6903 and following the instructions.
|
||||
![]() |
![]() |
||||
By Mail | At The Virtual Annual Meeting | ||||
If you received your proxy materials in the mail, you may complete, sign and return the accompanying proxy and voting instruction card in the postage-paid envelope provided.
|
If you are a stockholder of record you may electronically attend the virtual annual meeting and vote your shares at http://www.virtualshareholdermeeting.com/SAIC2021 during the meeting. You will need to provide your 16-digit control number that is on your Notice of Internet Availability of Proxy Materials or your proxy card if you receive a printed copy of the proxy materials by mail.
|
Science Application International Corporation | ||||||||
2021 Proxy Statement | 6
|
INFORMATION ABOUT THE ANNUAL MEETING OF STOCKHOLDERS |
7 | saic.com
|
INFORMATION ABOUT THE ANNUAL MEETING OF STOCKHOLDERS |
Science Application International Corporation | ||||||||
2021 Proxy Statement | 8
|
PROPOSAL 1 - ELECTION OF DIRECTORS |
9 | saic.com
|
PROPOSAL 1 - ELECTION OF DIRECTORS |
![]() |
Age:
72
Director since:
2013
Independent
|
Select Qualifications and Skills:
Leadership and Executive Management Experience:
Served as Global Coordinating Partner at Ernst & Young LLP ("EY"), a multinational professional services firm.
Financial Expertise:
Over 40 years of experience, including 32 years as a partner in EY's accounting and auditing practices.
Industry Knowledge and Experience:
Government Contracting
:
Served as Senior Advisory Partner for a number of EY’s largest clients and served on EY’s Senior Governing Board;
Aerospace and Defense Industry
:
Served as EY’s Aerospace & Defense Practice Leader for over 15 years.
Director Experience:
Mr. Bedingfield has served on the Board of Trustees for the University of Maryland at College Park Foundation since 2000 and is currently an Emeritus Trustee, and the Board of Directors for GeoPark Limited since 2015, where he is also the Chair of the Audit and Nominating and Corporate Governance Committees.
The Board believes that Mr. Bedingfield’s financial expertise and his deep knowledge and experience in government contracting gained through decades of serving major companies in our industry provide important contributions to the Board.
|
|||||||||
Committees:
Audit (Chair); Compensation
|
![]() |
Age:
67
Director since:
2019
Independent
|
Select Qualifications and Skills:
Leadership Experience:
Currently serves as a human capital consultant for various technology firms. From 2014 until 2018, she served as the Senior Vice President and Chief Human Resources Officer of Brocade Communications, a technology company specializing in data and storage networking products, where she strategically led global, cross-functional teams through multiple acquisitions and divestitures. Ms. Goode also served as Vice President of Human Resources for the Product Development Group at Nortel Networks, a former multinational telecommunications and data networking equipment manufacturer, from 1997 until 2001.
Director Experience
: In 2019, Ms. Goode served on the Board of Directors for WageWorks, an employee benefits administration company. Since 2020, Ms. Goode has served on the Board of Directors for Carney Technology Acquisition Corporation II, a special purpose acquisition company.
Ms. Goode brings more than 35 years of distinguished business experience in the fields of human resources and human capital management. The Board believes that her expertise provides significant value to our Board and the company in talent management, acquisition and retention.
|
|||||||||
Committees:
Compensation; Nominating
|
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 10
|
PROPOSAL 1 - ELECTION OF DIRECTORS |
![]() |
Age:
46
Director since:
2021
Independent
|
Select Qualifications and Skills:
Leadership and Executive Management Experience:
Since January 2021, Dr. Graham has served as the Director and Global Head of Healthcare for YouTube, LLC, an online video-sharing platform and subsidiary of Alphabet Inc. (Nasdaq: GOOGL). From 2019 until 2021, Dr. Graham served as the Chief Community Health Officer for CVS Health Corporation (NYSE: CVS), a diversified health services company, and from 2013 until 2019, he served in various roles for Aetna Inc., a health insurance company, including as the President of the Aetna Foundation and the Vice President for Community Health.
Healthcare and Industry Expertise:
Dr. Graham holds a medical degree from Yale School of Medicine, and a Master of Public Health from Yale School of Public Health. A cardiologist and professor of medicine, he was Deputy Assistant Secretary to the U.S. Health and Human Services Department under Presidents Barack Obama and George W. Bush, in addition he led the Office of Minority Health and the federal government’s first National Health Disparities Plan. An elected member of the National Academy of Medicine, he contributes to several boards including the Institute of Medicine Board on Population Health, the National Quality Forum, and the National Heart, Lung, and Blood Institute Advisory Council.
The Board believes that Dr. Graham’s extensive healthcare expertise and leadership qualifications in various senior roles within the healthcare arena provides a unique and dynamic skill set to the Board.
|
|||||||||
Committees:
Compensation
|
![]() |
Age:
70
Director since:
2013
Independent
|
Select Qualifications and Skills:
Leadership and Executive Management Experience:
Serves as President and Chief Executive Officer of the Center for Strategic & International Studies since 2000. Served as Chairman of the Defense Policy Board Advisory Committee for four Secretaries of Defense for 10 years.
Industry Knowledge and Experience:
Served as U.S. Deputy Secretary of Defense from 1997 to 2000 and Under Secretary of Defense (Comptroller) from 1993 to 1997.
Director Experience:
Dr. Hamre was previously a Director of Exelis, Inc., a former global aerospace, defense, information and services company, until May 2015 and a Director of Leidos Holdings, Inc., our former parent, until September 2016. Since 2018, Dr. Hamre has served as a Director for ImperativeCare, a neurovascular device company. Dr. Hamre also served on the Board of Directors of the MITRE Corporation, a non-profit organization, from 2001 to October 2018, as well as Chairman of the Board of Directors from May 2016 to October 2018.
Dr. Hamre is a leading expert on issues of national security, defense and international affairs with extensive experience working in these areas from serving in high-ranking positions at the U.S. Department of Defense. His particular expertise in matters key to our business, as well as his executive management experience as Chief Executive Officer of a leading public policy research institution, offer important contributions to the Board.
|
|||||||||
Committees:
Nominating; Risk Oversight (Chair)
|
11 | saic.com
|
PROPOSAL 1 - ELECTION OF DIRECTORS |
![]() |
Age:
55
Director since:
2019
Independent
|
Select Qualifications and Skills:
Leadership Experience:
Currently serves as a Partner and Chief Technology Officer for JC2 Ventures, a Silicon Valley based venture capital firm. Prior to her current role, Ms. Kanouff served from 2014 to 2019 as the Senior Vice President and General Manager for the service provider business line of Cisco Systems, Inc., a global leader in information technology, networking and cybersecurity solutions. Prior to her role with Cisco, from 2012 to 2014, Ms. Kanouff served as Executive Vice President of Engineering and Technology for Cablevision Systems Corporation, a cable television provider and multiple system operator, and from 2010 to 2012, served as President of SeaChange International, a video management solutions provider.
Director Experience
: Ms. Kanouff has served on the Board of Directors for Sprinklr, a software management and enterprise social media marketing firm, since 2018, and Safe Security, a cyber risk quantification company, since 2020. She also has served on the Board of Directors for Amdocs, a software and services provider to communications and media companies, since 2020.
The Board believes that Ms. Kanouff’s diverse background in the technology industry, with over 25 years of extensive leadership positions and experience, combined with a solid strategy and investment background, provide great insight and value to our Board.
|
|||||||||
Committees:
Audit; Risk Oversight
|
![]() |
Age:
60
Director since:
2019
Chief Executive Officer
|
Select Qualifications and Skills:
Leadership and Executive Management Experience:
Serves as our Chief Executive Officer and a Director since 2019. Previously served as Chief Operating Officer from 2017 until July 2019, where she was responsible for overseeing daily operations of the company, including its long-term strategy for sustained profitable growth. Ms. Keene joined the company in 2012, holding several leadership roles including President of the Company’s Global Markets & Mission sector and Senior Vice President of Corporate Strategy.
Director Experience:
Since 2020, Ms. Keene has served as a member of the Board of Directors for each of Automatic Data Processing, Inc., a provider of human resources management software and services, INOVA Hospital System, a non-profit health organization, and VA Ready Initiative, a non-profit organization focused on economic development initiatives in response to COVID-19.
Industry Knowledge and Experience:
Over 35 years of experience in the information systems and technology services industry, with 25 years in executive management positions. Prior to joining SAIC, Ms. Keene was the Senior Vice President and General Manager for U.S. Enterprise Markets at CGI Group Inc., a global information technology consulting, systems integration, outsourcing and solutions company listed on the New York Stock Exchange, from 2004 to 2012, leading the company’s U.S. expansion in all aspects of strategy development, operational execution and leadership development. She previously held various roles in the communications and IT industry.
The Board believes that Ms. Keene’s extensive market knowledge, leadership skills and management ability proven throughout her leadership roles and as an executive officer with our company make her highly qualified to serve on our Board. In addition, our Board believes that the company’s Chief Executive Officer should serve on the Board of Directors to help communicate the Board’s priorities to management as well as bring management’s perspective on matters considered by the Board.
|
|||||||||
Committee:
Risk Oversight
|
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 12
|
PROPOSAL 1 - ELECTION OF DIRECTORS |
![]() |
Age:
62
Director since:
2015
Independent
|
Select Qualifications and Skills:
Leadership Experience:
President of Blend Labs, Inc., a Silicon Valley enterprise software company. Previously served as President and Chief Executive Officer of the Federal National Mortgage Association, known as Fannie Mae, from June 2012 until October 2018.
Executive Management and Legal Expertise:
In addition to his recent executive leadership roles as President of Blend Labs and President and CEO of Fannie Mae, Mr. Mayopoulos was Chief Administrative Officer of Fannie Mae from 2010 to 2012, and General Counsel and Corporate Secretary of Fannie Mae from 2009 to 2012. Prior to joining Fannie Mae, he was Executive Vice President and General Counsel of Bank of America Corporation.
Financial Expertise:
Mr. Mayopoulos has held executive leadership roles in financial institutions that have required significant financial expertise and capital markets knowledge. He also serves on the Audit Committee and Chairs the Operational Risk Committee of the Board of Directors of Lending Club Corporation, a sole-spectrum fintech marketplace bank.
Director Expertise:
In addition to Mr. Mayopoulos' service as a member of the Board of Directors for Lending Club Corporation, he also serves on the Board of Directors for Blend Labs, Inc., a digital lending platform for mortgages and consumer banking, and the Board of Directors for Valon Technologies, Inc., a digital mortgage services company.
Mr. Mayopoulos has over 30 years of professional experience. His valuable contributions to our Board include his executive management experience, his experience in finance and capital markets, his legal background and his experience operating in highly regulated businesses.
|
|||||||||
Committees:
Audit; Nominating (Chair)
|
![]() |
Age:
61
Director since:
2019
Independent
|
Select Qualifications and Skills:
Leadership Experience:
With over 30 years of government service, Katharina (Katrina) McFarland is widely recognized as a leading subject-matter expert on government procurement. She serves as Chair of the Board of Army Research and Development at the National Academies of Science, Commissioner of the National Security Commission on Artificial Intelligence, and as a Director on the Procurement Round Table. She was previously the Assistant Secretary of Defense for Acquisition (2012 to 2017) and acting Assistant Secretary of the Army (Acquisition, Logistics & Technology) (2016 to 2017). She was President of the Defense Acquisition University from 2010 to 2012. From 2006 to 2010, Ms. McFarland was the Director of Acquisition, Missile Defense Agency.
Director Experience
: Ms. McFarland serves as an advisor or a Director to several Boards of Directors, including Raytheon Missile Systems Division Senior Advisory Board, Cypress International Senior Strategy Group, Transunion Corporation Advisory Board, Exyn Technologies Board of Directors, and Sehlke, Inc, Senior Advisory Board. Ms. McFarland was a Director for Engility from 2017 to January 2019.
Ms. McFarland brings substantial experience in defense acquisition, program management, logistics and technology. In particular, her experience with the U.S. Department of Defense, Department of Army, and Intelligence Community procurement provides valuable insight to the Board.
|
|||||||||
Committees:
Nominating; Risk Oversight
|
13 | saic.com
|
PROPOSAL 1 - ELECTION OF DIRECTORS |
![]() |
Age:
66
Director since:
2013
Independent
Chair of the Board
|
Select Qualifications and Skills:
Leadership and Executive Management Experience:
Served as President of CGI Technology and Solutions, Inc. ("CGI"), a wholly-owned U.S. subsidiary of CGI Group, one of the largest independent information technology firms in North America, from May 2004 until her retirement at the end of 2011. Ms. Morea also served as a Director for CGI from February 2012 to May 2013. Ms. Morea currently serves as an Operating Advisor at The Carlyle Group, a private equity firm, serving as a Director for several technology portfolio companies.
Industry Knowledge and Experience:
Information and Technology Expertise:
Over 30 years of experience; nationally recognized executive in IT professional services management; and led CGI’s IT and business process services in the U.S. and India for large enterprises in financial services, healthcare, telecommunications and government.
Director Experience:
Ms. Morea served as a member of the Board of Directors of SunTrust Banks, Inc. from 2012 until December 2019, and has served as a member of the Board of Directors of Inova Health System since 2015, and Truist Financial Corp. since December 2019.
The Board believes that Ms. Morea’s executive management experience and information technology expertise provide valuable leadership experience and market knowledge of a significant segment of our business.
|
|||||||||
Committees:
Nominating; Risk Oversight
|
![]() |
Age:
63
Director since:
2013
Independent
|
Select Qualifications and Skills:
Leadership:
Served as a partner of Accenture plc ("Accenture"), a management consulting, technology and outsourcing services firm, until his retirement in 2011 after a 30-year career.
Financial Expertise and Industry Experience:
Consulting and Technology Systems:
While at Accenture, Mr. Shane was the Managing Partner of the North America Public Service business responsible for Accenture’s U.S. federal, state and local and Canadian federal and provincial business. He also held several other senior management positions, including those where he led consulting engagements for many of the largest banking institutions in the United States. Following his retirement from Accenture in 2011, Mr. Shane joined LH&P, LLC ("LH&P"), a boutique consulting company, where he provided strategic, organizational and business advice to senior executives in some of the largest U.S. financial services companies. Mr. Shane retired from LH&P in March 2018. In March 2020, Mr. Shane rejoined LH&P as an independent consultant.
Director Experience:
Mr. Shane previously served on the Board of Directors for ZPower, LLC, a battery technology company, from 2003 until his voluntary retirement in 2019. Mr. Shane has served on the Board of Directors for MAXIMUS Federal Services, an outsourcing company that provides business process services to government health and human services agencies, since 2013. He also served as a Director for Dispersive Networks, LLC, a virtual network solutions provider, from 2014 until his voluntary retirement in January 2020.
The Board believes that Mr. Shane’s expertise in financial matters and the implementation of significant, mission-critical technology systems for the U.S. government as well as state and local governments offer perspectives that our Board considers valuable to us as a leading provider of technical, engineering and enterprise information technology services to government customers.
|
|||||||||
Committees:
Audit; Compensation (Chair)
|
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 14
|
CORPORATE GOVERNANCE |
15 | saic.com
|
CORPORATE GOVERNANCE |
✓
expertise and involvement in areas relevant to our business such as defense, intelligence, science, finance, government or commercial and international business;
✓
interpersonal skills, substantial personal accomplishments and diversity as to gender, age, race, ethnic background and experience;
✓
commitment to business ethics, professional reputation, independence and understanding of the responsibilities of a director and the governance processes of a public company;
✓
demonstrated leadership, with the ability to exercise sound judgment informed by diversity of experience and perspectives; and
✓
benefits from the continuing service of qualified incumbent directors in promoting stability and continuity, contributing to the Board’s ability to work together as a collective body and giving the company the benefit of experience and insight that its directors have accumulated during their tenure.
|
✓
a majority of directors must meet the independence criteria established by the Board;
✓
based upon the range of 7 to 14 directors currently specified in our bylaws, no more than three directors may be an employee of SAIC;
✓
only a full-time employee who serves as either the Chief Executive Officer or one of his or her direct reports will be considered as a candidate for an employee director position; and
✓
no director nominee may be a consultant to the company.
|
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 16
|
CORPORATE GOVERNANCE |
•
planning the Board’s annual schedule of meetings and agendas, in consultation with the Chief Executive Officer and Corporate Secretary and other directors as appropriate;
•
coordinating with the Chief Executive Officer and the Corporate Secretary to ensure that the Board receives the appropriate quantity and quality of information in a timely manner to enable it to make informed decisions;
•
chairing all meetings of the Board and of the independent directors in executive session and ensure that meetings are conducted efficiently and effectively;
•
facilitating full and candid Board discussions, ensuring all directors express their views on key Board matters and assist the Board in achieving a consensus;
•
working with committee chairs to ensure that each committee functions effectively and keeps the Board apprised of actions taken;
•
building consensus, developing teamwork and a cohesive Board culture and facilitating formal and informal communication with and among directors; and
•
serving as the liaison between the Board and company management.
|
Board of Directors | |||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
Audit Committee | Risk Oversight Committee |
Human Resources
and Compensation
Committee
|
Nominating and
Corporate Governance
Committee
|
||||||||||||||||||||||||||||||||
The Audit Committee evaluates the company’s guidelines and policies regarding risk assessment and risk management, including risks related to internal control over financial reporting, the company’s major financial risk exposures and the steps management has taken to monitor and control those exposures. | The Risk Oversight Committee reviews and provides oversight of the company's regulatory, enterprise and strategic risk; ethics, compliance, and corporate responsibilities; and its classified and business operations. |
The Human Resources and Compensation Committee assesses risks potentially arising from the company’s human resources and compensation policies and practices.
|
The Nominating and Corporate Governance Committee identifies and recommends individuals for selection to the Board, develops and recommends corporate governance guidelines to the Board, makes recommendations regarding the size, composition and charters of the Board and oversees the evaluation of the Board and Board committees.
|
17 | saic.com
|
CORPORATE GOVERNANCE |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 18
|
CORPORATE GOVERNANCE |
![]() |
AUDIT COMMITTEE
The specific responsibilities of the Audit Committee are further set forth in its charter and include:
|
|||||||
Members
(1)(2)
|
Roles and Responsibilities
|
Meetings in Fiscal 2021 | ||||||
• Robert A. Bedingfield (Chair)
• Yvette M. Kanouff
• David M. Kerko
(3)
• Timothy J. Mayopoulos
• Steven R. Shane
|
• Internal Controls and Disclosure Controls—
Review and provide feedback on management’s assessment of, and the report on, the effectiveness of the company’s internal control over financial reporting, and the independent, registered public accounting firm’s related report.
• Independent Audit—
Appoint, retain, oversee, evaluate, and if necessary, replace the company's independent registered public accounting firm, including the lead audit partner, for the purpose of preparing or issuing an audit report on our annual consolidated financial statements and performing other audit, review or attest services; pre-approve all audit and non-audit services and related fees; and evaluate the independent registered public accounting firm’s qualifications, performance and independence, in light of among other things, non-audit services and fees.
• Internal Audit—
Review the qualifications, structure and performance of the internal audit function; review and approve the company’s internal audit plan; and periodically review findings from completed audits, status of major audits in process, and any significant difficulties, disagreements with management or restrictions encountered in the scope of the company's internal audit department’s work.
• Financial Reporting—
Review and discuss with management, the independent registered public accounting firm and the internal auditor the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q; and discuss with the independent registered public accounting firm the auditor’s judgments and recommendations about the accounting principles used to prepare our consolidated financial statements.
• Ethical and Legal Compliance—
Review the effectiveness of our system for monitoring compliance with laws and regulations; establish procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters (including procedures for receiving and handling complaints on a confidential and anonymous basis); and evaluate and handle any complaints submitted to or reported to the Audit Committee.
• Other Responsibilities—
Discuss and evaluate our guidelines and policies regarding risk assessment and risk management; discuss our major financial risk exposures and the steps management has taken to monitor and control those exposures; and review our litigation, government investigation and legal compliance matters that could have a significant impact on our financial statements.
|
4 |
19 | saic.com
|
CORPORATE GOVERNANCE |
![]() |
RISK OVERSIGHT COMMITTEE
The responsibilities of the Risk Oversight Committee are further set forth in its charter and include:
|
|||||||
Members
|
Roles and Responsibilities
|
Meetings held in Fiscal 2021
|
||||||
•
John J. Hamre (Chair)
•
Yvette M. Kanouff
•
Nazzic S. Keene
•
Katharina G. McFarland
•
Donna S. Morea
|
• Monitoring and Overseeing Regulatory, Enterprise and Strategic Risk Areas, including reviewing the following—
operational, compliance and reputation risk management activities; and enterprise legal and strategic risk management activities, material regulatory matters, technology oversight and cyber risk.
• Monitoring Policies and Practices Relating to Ethics, Compliance, and Corporate Responsibility, including reviewing the following—
our
Code of Conduct; third-party risk; safety; environmental, sustainability and governance matters; contributions to charitable and other tax-exempt organizations; and political contributions and government relations.
• Overseeing Case Management and Personal Conflict of Interest Review Process for Executive Officers and Independent Directors, including—
the
receipt, retention and treatment of complaints involving alleged misconduct, unethical behavior, violation of the Company’s policies or potential conflict of interest involving an executive officer or any other person or matter of concern presented to the Committee by the Board.
• Overseeing the Company's Classified Business, including—
the
general oversight of the Company's classified business activities and making recommendations to the Board and management concerning the review of the strategic, operational and financial aspects of the Company’s classified business; and the review of policies, processes, procedures, training, risk assessment and management activities applicable to the Company’s classified business activities to the extent that they deviate from those applicable to the Company’s non-classified business activities.
|
4 |
![]() |
HUMAN RESOURCES AND COMPENSATION COMMITTEE
The responsibilities of the Human Resources and Compensation Committee are further set forth in its charter and include:
|
|||||||
Members
(1)
|
Roles and Responsibilities
|
Meetings held in Fiscal 2021
|
||||||
•
Steven R. Shane (Chair)
•
Robert A. Bedingfield
•
Carol A. Goode
•
Garth N. Graham
(2)
•
David M. Kerko
(3)
|
•
Determining the compensation of our Chief Executive Officer and reviewing and approving the compensation of our other executive officers;
•
Reviewing and evaluating, with the Chief Executive Officer, the long-range plans for management succession;
•
Exercising all rights, authority and functions reserved to such committee under all of our equity, retirement and other compensation plans;
•
Approving and making recommendations to the Board regarding non-employee director compensation;
•
Preparing an annual report on executive compensation for inclusion in our proxy statement or Annual Report on Form 10-K in accordance with the rules and regulations of the SEC; and
•
Periodically reviewing our human resources strategy, policies and programs.
|
5 |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 20
|
CORPORATE GOVERNANCE |
![]() |
NOMINATING AND CORPORATE GOVERNANCE
COMMITTEE
The responsibilities of the Nominating and Corporate Governance Committee are further set forth in its charter and include:
|
|||||||
Members
(1)
|
Roles and Responsibilities
|
Meetings held in Fiscal 2021 | ||||||
•
Timothy J. Mayopoulos (Chair)
•
Carol A. Goode
•
John J. Hamre
•
Katharina G. McFarland
•
Donna S. Morea
|
•
Evaluating, identifying and recommending director nominees, including nominees proposed by stockholders;
•
Reviewing and making recommendations regarding the composition and procedures of the Board;
•
Making recommendations regarding the size, composition and charters of the Board’s committees;
•
Developing and recommending to the Board a set of corporate governance principles, including recommending an independent director to serve as non-executive Chair of the Board or as Lead Director (as applicable); and
•
Developing and overseeing an annual self-evaluation process of the Board and its committees.
|
3 |
21 | saic.com
|
CORPORATE GOVERNANCE |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 22
|
CORPORATE GOVERNANCE |
Name
(1)
|
Fees earned or paid in cash
($) (2) |
Stock awards
($) (3) |
Total
($)
|
||||||||
Robert A. Bedingfield
|
157,375 | 157,500 | 314,875 | ||||||||
Carol A. Goode
|
137,375 | 157,500 | 294,875 | ||||||||
John J. Hamre
|
126,375 | 157,500 | 283,875 | ||||||||
Yvette M. Kanouff
|
137,375 | 157,500 | 294,875 | ||||||||
David M. Kerko
|
113,375 | 157,500 | 270,875 | ||||||||
Timothy J. Mayopoulos
|
129,691 | 157,500 | 287,191 | ||||||||
Katharina G. McFarland
|
113,375 | 157,500 | 270,875 | ||||||||
Donna S. Morea
|
309,125 | 157,500 | 466,625 | ||||||||
Steven R. Shane
|
155,375 | 157,500 | 312,875 |
23 | saic.com
|
CORPORATE GOVERNANCE |
Name
|
Unvested stock units | ||||
Robert A. Bedingfield
|
1,734 | ||||
Carol A. Goode
|
1,734 | ||||
John J. Hamre
|
1,734 | ||||
Yvette M. Kanouff
|
1,734 | ||||
David M. Kerko
|
1,734 | ||||
Timothy J. Mayopoulos
|
1,734 | ||||
Katharina G. McFarland
|
1,734 | ||||
Donna S. Morea
|
1,734 | ||||
Steven R. Shane
|
1,734 |
Name
|
Aggregate shares subject to outstanding options
|
||||
Robert A. Bedingfield
|
26,495 | ||||
Carol A. Goode
|
2,006 | ||||
John J. Hamre
|
8,451 | ||||
Yvette M. Kanouff
|
2,006 | ||||
David M. Kerko
|
4,313 | ||||
Timothy J. Mayopoulos
|
17,481 | ||||
Katharina G. McFarland
|
4,313 | ||||
Donna S. Morea
|
26,495 | ||||
Steven R. Shane
|
17,481 |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 24
|
CORPORATE GOVERNANCE |
25 | saic.com
|
PROPOSAL 2 - ADVISORY (NON-BINDING) VOTE ON EXECUTIVE COMPENSATION |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 26
|
COMPENSATION DISCUSSION AND ANALYSIS |
Name
|
Title
|
||||
Nazzic S. Keene |
Chief Executive Officer
|
||||
Prabu Natarajan
(1)
|
Executive Vice President, Chief Financial Officer | ||||
Charles A. Mathis
(1)
|
Former Executive Vice President, Chief Financial Officer | ||||
Robert S. Genter | President, Defense and Civilian Sector | ||||
Steven G. Mahon | Executive Vice President, General Counsel & Corporate Secretary | ||||
Michael W. LaRouche | President, National Security and Space Sector |
27 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 28
|
COMPENSATION DISCUSSION AND ANALYSIS |
![]() |
![]() |
29 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
At SAIC, we ...
|
||
ü
Believe in pay for performance—simply put, we reward those who perform.
ü
Conduct an annual review by the Committee to establish a group of comparable companies to be used in compensation decisions.
ü
Review and consider feedback provided by our stockholders related to executive compensation matters.
ü
Mitigate against imprudent risk-taking through balancing features in the design of our compensation programs.
ü
Subject cash and equity-based incentive compensation to a “clawback” policy if there is a material restatement of our financial results for any reason or if the employee was involved in misconduct.
ü
Require significant stock ownership under our stock ownership guidelines.
ü
Use an independent compensation consultant who reports directly to the Committee.
ü
Provide “double-trigger” provisions for certain change in control benefits.
|
||
At SAIC, we do not ...
|
||
×
Permit cash buyout or re-pricing of underwater stock options.
×
Guarantee any bonus payouts to executive officers.
×
Provide employment agreements for executive officers.
×
Provide golden parachute excise tax gross-ups on change in control benefits.
×
Permit hedging or pledging of company stock or purchasing company stock on margin by our executive officers.
×
Offer pension benefits to our executive officers or other employees.
×
Provide excessive perquisites for executive officers.
|
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 30
|
COMPENSATION DISCUSSION AND ANALYSIS |
31 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 32
|
COMPENSATION DISCUSSION AND ANALYSIS |
Booz Allen Hamilton |
L-3 Communications Holdings, Inc.
(1)
|
||||
CACI International Inc | Leidos, Inc. | ||||
CGI Group, Inc. | ManTech International Corporation | ||||
Collins Aerospace | MAXIMUS, Inc. | ||||
Harris Corporation
(1)
|
Parsons Corporation | ||||
Huntington Ingalls Industries | Perspecta | ||||
Jacobs Engineering Group, Inc. | Unisys Corporation | ||||
KBR, Inc. |
Name
|
Fiscal 2021 Base Salary |
Percentage Increase from Fiscal 2020 Base Salary
|
||||||
Nazzic S. Keene
|
$1,075,000 | 7.5 | % | |||||
Prabu Natarajan
(1)
|
$600,000 | — | ||||||
Charles A. Mathis
|
$575,000 | 4.5 | % | |||||
Robert S. Genter | $600,000 | 33.3 | % | |||||
Steven G. Mahon | $600,000 | 4.3 | % | |||||
Michael W. LaRouche | $475,000 | 18.8 | % |
33 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
Financial Measures
(1)
|
Weight | Threshold | Target | Maximum |
2021 Actual
(1)
|
% of Target Achieved | Payout % |
2020 Actual
(1)
|
||||||||||||||||||
Adjusted EBITDA | 50 | % |
$554M
|
$652M
|
$750M
|
$643M | 98.6 | % | 95.4 | % |
$538M
|
|||||||||||||||
Revenue | 35 | % |
$6.593B
|
$7.326B
|
$8.059B
|
$7.318B | 99.9 | % | 99.5 | % |
$6.379B
|
|||||||||||||||
Adjusted Operating Cash Flow | 15 | % |
$392M
|
$490M
|
$588M
|
$498M | 101.6 | % | 108.2 | % |
$454M
|
|||||||||||||||
Weighted Average for Financial Goals | 98.7 | % |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 34
|
COMPENSATION DISCUSSION AND ANALYSIS |
Name | Base Salary | STI Target as % of Base Salary |
Financial Score
(1)
|
Cash Incentive Amount Paid | ||||||||||
Nazzic S. Keene
|
$1,075,000 | 130 | % | 98.7 | % | $1,655,702 | ||||||||
Charles A. Mathis | $575,000 | 85 | % | 98.7 | % | $482,543 | ||||||||
Robert S. Genter | $600,000 | 80 | % | 101.2 | % | $534,283 | ||||||||
Steven G. Mahon | $600,000 | 75 | % | 98.7 | % | $533,142 | ||||||||
Michael W. LaRouche | $475,000 | 80 | % | 103.4 | % | $432,379 |
![]() |
Performance Shares
—Incentivize our named executive officers to achieve specific measurable financial goals over a three-year performance cycle. Earned shares vest and are issued at the end of the performance cycle and range from 0% for below threshold performance to 200% of target number of shares for maximum performance. PSAs are granted in overlapping annual cycles and serve as a tool to align pay and company performance and to retain our named executive officers. Dividend equivalents are accumulated in cash and are paid at the end of the three-year performance cycle to the extent that the underlying share awards are earned.
|
||||
Restricted Stock Units
—Align pay and company performance as reflected in our stock price, encourage retention of our named executive officers’ services and promote continued investment by our executives in company stock. RSUs awarded in fiscal 2021 vest over a three-year period in 33% installments at each anniversary of the grant date. Dividend equivalents on unvested RSUs accumulate in cash and are paid when and if the underlying RSUs vest.
|
|||||
Stock Options
—Align named executive officer and stockholder interests by having value only if the stock price increases over the term of the option. Stock options vest in 33% installments at the end of each of the first three years following grant and expire at the end of the seventh year.
|
Performance Measures
|
Weight
|
Description
|
||||||
Cumulative Adjusted EBITDA
|
60% |
A three-year average EBITDA growth goal measured against performance targets set at the beginning of the performance period
|
||||||
Adjusted Annual Operating Cash Flow
|
40% |
An annual goal for each year is set at the beginning of the performance period
|
35 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
Performance Measures
|
Performance Period | Weight |
Threshold
50% |
Target 100% |
Maximum
150% |
Actual
(1)
|
% of Target
Achieved |
Payout | ||||||||||||||||||
Adjusted Cumulative Operating Income | FY19-21 | 60% |
$1.386B
|
$1.597B
|
$1.710B
|
$1.518B | 95.0% | 81.2% | ||||||||||||||||||
Adjusted Operating Cash Flow | FY19 |
$227M
|
$267M
|
$299M
|
$241M | 90.3% | 67.5% | |||||||||||||||||||
FY20
|
40% |
$419M
|
$482M
|
$525M
|
$489M | 101.5% | 108.1% | |||||||||||||||||||
FY21
|
$461M
|
$538M
|
$589M
|
$805M | 149.6% | 150.0% | ||||||||||||||||||||
Weighted Average for Financial Goals
|
92.2% |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 36
|
COMPENSATION DISCUSSION AND ANALYSIS |
37 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 38
|
COMPENSATION DISCUSSION AND ANALYSIS |
39 | saic.com
|
COMPENSATION DISCUSSION AND ANALYSIS |
Name and
principal position
|
Fiscal
Year (1) |
Salary
($)
|
Bonus
($) (2) |
Stock
awards
($) (3) |
Option
awards
($) (3) |
Non-equity
incentive plan compensation ($) (4) |
All other
compensation
($) (5) |
Total ($) | ||||||||||||||||||
Nazzic S. Keene
Chief Executive Officer
|
2021 | 1,063,462 | — | 3,150,053 | 1,050,008 | 1,655,702 | 17,477 | 6,936,702 | ||||||||||||||||||
2020 | 961,539 | — | 2,953,210 | 950,014 | 1,227,000 | 14,085 | 6,105,848 | |||||||||||||||||||
2019 | 734,616 | — | 1,500,006 | 500,008 | 985,500 | 16,237 | 3,736,367 | |||||||||||||||||||
Prabu Natarajan
Chief Financial Officer
|
2021 | 34,615 | 500,000 | 500,078 | — | — | — | 1,034,693 | ||||||||||||||||||
Charles A. Mathis
Former Executive Vice President and
Chief Financial Officer
|
2021 | 571,154 | — | 900,068 | 300,017 | 482,543 | 13,000 | 2,266,782 | ||||||||||||||||||
2020 | 546,154 | — | 917,052 | 295,015 | 458,898 | 12,677 | 2,229,796 | |||||||||||||||||||
2019 | 525,000 | — | 825,118 | 275,004 | 561,940 | 15,079 | 2,202,141 | |||||||||||||||||||
Robert S. Genter
President, Defense and Civilian Sector |
2021 | 576,923 | — | 1,000,041 | 250,014 | 534,283 | 11,400 | 2,372,661 | ||||||||||||||||||
2020 | 446,154 | — | 616,348 | — | 327,337 | 9,738 | 1,399,577 | |||||||||||||||||||
Steven G. Mahon
Executive Vice
President and General Counsel
|
2021 | 596,154 | — | 750,020 | 250,014 | 533,142 | 13,700 | 2,143,030 | ||||||||||||||||||
2020 | 563,461 | — | 777,222 | 250,015 | 423,315 | 11,654 | 2,025,667 | |||||||||||||||||||
2019 | 492,298 | — | 600,071 | 200,015 | 459,900 | 11,185 | 1,763,469 | |||||||||||||||||||
Michael W. LaRouche President, National Security and Space Sector | 2021 | 463,462 | — | 812,592 | 187,506 | 432,379 | 14,054 | 1,909,993 | ||||||||||||||||||
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 40
|
EXECUTIVE COMPENSATION |
Estimated future payouts under
non-equity incentive plan awards (1) |
Estimated future payouts under equity incentive plan awards
(2)
|
All other
stock
awards;
number of shares of stock or units (#)
(3)
|
All other
option
awards;
number of securities
underlying options
(#) (4) |
Exercise
or base price of
option awards ($/share)
(5)
|
Closing
market price on the date of grant ($) |
Grant date
fair value
of stock and
option awards ($)
(6)
|
||||||||||||||||||||||||||||||||||||||
Name |
Award
type
|
Grant
date
|
Approval
date
|
Threshold
($) |
Target
($)
|
Maximum
($) |
Threshold
(#) |
Target
(#) |
Maximum
(#) |
|||||||||||||||||||||||||||||||||||
Ms. Keene | Cash | — | — | 698,750 | 1,397,500 | 2,795,000 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Options | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | — | 60,624 | 73.77 | 71.30 | 1,050,008 | |||||||||||||||||||||||||||||||
PSA | 04/03/2020 | 03/24/2020 | — | — | — | 14,234 | 28,467 | 56,934 | — | — | — | — | 2,100,011 | |||||||||||||||||||||||||||||||
RSU | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | 14,234 | — | — | — | 1,050,042 | |||||||||||||||||||||||||||||||
Mr. Natarajan | RSU | 01/04/2021 | 12/10/2020 | — | — | — | — | — | — | 5,284 | — | — | — | 500,078 | ||||||||||||||||||||||||||||||
Mr. Mathis | Cash | — | — | 244,375 | 488,750 | 977,500 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Options | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | — | 17,322 | 73.77 | 71.30 | 300,017 | |||||||||||||||||||||||||||||||
PSA | 04/03/2020 | 03/24/2020 | — | — | — | 4,067 | 8,134 | 16,268 | — | — | — | — | 600,045 | |||||||||||||||||||||||||||||||
RSU | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | 4,067 | — | — | — | 300,023 | |||||||||||||||||||||||||||||||
Mr. Genter | Cash | — | — | 240,000 | 480,000 | 960,000 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Options | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | — | 14,435 | 73.77 | 71.30 | 250,014 | |||||||||||||||||||||||||||||||
PSA | 04/03/2020 | 03/24/2020 | — | — | — | 3,389 | 6,778 | 13,556 | — | — | — | — | 500,013 | |||||||||||||||||||||||||||||||
RSU | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | 3,389 | — | — | — | 250,007 | |||||||||||||||||||||||||||||||
RSU | 12/11/2020 | 12/10/2020 | — | — | — | — | — | — | 2,509 | — | — | — | 250,022 | |||||||||||||||||||||||||||||||
Mr. Mahon | Cash | — | — | 225,000 | 450,000 | 900,000 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Options | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | — | 14,435 | 73.77 | 71.30 | 250,014 | |||||||||||||||||||||||||||||||
PSA | 04/03/2020 | 03/24/2020 | — | — | — | 3,389 | 6,778 | 13,556 | — | — | — | — | 500,013 | |||||||||||||||||||||||||||||||
RSU | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | 3,389 | — | — | — | 250,007 | |||||||||||||||||||||||||||||||
Mr. LaRouche | Cash | — | — | 190,000 | 380,000 | 760,000 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||
Options | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | — | 10,826 | 73.77 | 71.30 | 187,506 | |||||||||||||||||||||||||||||||
PSA | 04/03/2020 | 03/24/2020 | — | — | — | 2,542 | 5,084 | 10,168 | — | — | — | — | 375,047 | |||||||||||||||||||||||||||||||
RSU | 04/03/2020 | 03/24/2020 | — | — | — | — | — | — | 2,542 | — | — | — | 187,523 | |||||||||||||||||||||||||||||||
RSU | 12/11/2020 | 12/10/2020 | — | — | — | — | — | — | 2,509 | — | — | — | 250,022 |
41 | saic.com
|
EXECUTIVE COMPENSATION |
Option awards
(1)
|
Stock awards
|
||||||||||||||||||||||||||||
Name
|
Grant Date |
Number of
securities underlying unexercised options (exercisable) (#) |
Number of
securities underlying unexercised options (unexercisable) (#) |
Option
exercise
price ($)
|
Option
expiration
date
|
Number of
shares of
stock or units that have not
vested (#)
(2)
|
Market value
of shares of
stock or units
that have not
vested ($)
(3)
|
Equity Incentive
Plan awards; number of
unearned shares, units or other rights that have not vested (#)
(4)
|
Equity Incentive Plan awards; market or payout value of unearned shares, units or
other rights that have not vested ($) (3) |
||||||||||||||||||||
Ms. Keene | 04/03/2020 | — | 60,624 | 73.77 | 04/02/2027 | 21,824 | 2,095,759 | 22,106 | 2,122,874 | ||||||||||||||||||||
05/22/2019
|
— | — | — | 8,879 | 852,637 | 16,972 | 1,629,847 | ||||||||||||||||||||||
04/05/2019
|
18,950 | 37,903 | 74.97 | 04/04/2026 | 8,449 | 811,357 | — | — | |||||||||||||||||||||
04/06/2018
|
17,300 | 8,651 | 85.31 | 04/05/2025 | 2,931 | 281,464 | — | — | |||||||||||||||||||||
06/16/2017
|
— | — | — | 339 | 32,554 | — | — | ||||||||||||||||||||||
04/07/2017
|
19,774 | — | 72.91 | 04/06/2024 | 1,115 | 107,073 | — | — | |||||||||||||||||||||
04/01/2016
|
29,302 | — | 53.34 | 03/31/2023 | — | — | — | — | |||||||||||||||||||||
04/10/2015
|
24,427 | — | 52.11 | 04/09/2022 | — | — | — | — | |||||||||||||||||||||
Mr. Natarajan | 01/04/2021 | — | — | — | 5,284 | 507,423 | — | — | |||||||||||||||||||||
Mr. Mathis | 04/03/2020 | — | 17,322 | 73.77 | 04/02/2027 | 6,235 | 598,747 | 6,317 | 606,619 | ||||||||||||||||||||
05/22/2019
|
— | — | — | 2,756 | 264,699 | 5,271 | 506,189 | ||||||||||||||||||||||
04/05/2019
|
5,884 | 11,771 | 74.97 | 04/04/2026 | 2,624 | 251,983 | — | — | |||||||||||||||||||||
04/06/2018
|
9,515 | 4,758 | 85.31 | 04/05/2025 | 1,612 | 154,800 | — | — | |||||||||||||||||||||
04/07/2017
|
— | — | — | 943 | 90,556 | — | — | ||||||||||||||||||||||
Mr. Genter | 12/11/2020 | — | — | — | 2,509 | 240,939 | — | — | |||||||||||||||||||||
04/03/2020 | — | 14,435 | 73.77 | 04/02/2027 | 5,195 | 498,876 | 5,264 | 505,507 | |||||||||||||||||||||
05/22/2019
|
— | — | — | 1,402 | 134,638 | 2,680 | 257,349 | ||||||||||||||||||||||
04/05/2019
|
— | — | — | 2,669 | 256,304 | — | — | ||||||||||||||||||||||
04/06/2018
|
— | — | — | 1,246 | 119,653 | — | — | ||||||||||||||||||||||
04/07/2017
|
— | — | — | 686 | 65,877 | — | — | ||||||||||||||||||||||
Mr. Mahon | 04/03/2020 | — | 14,435 | 73.77 | 04/02/2027 | 5,195 | 498,876 | 5,264 | 505,507 | ||||||||||||||||||||
05/22/2019
|
— | — | — | 2,336 | 224,325 | 4,468 | 429,019 | ||||||||||||||||||||||
04/05/2019
|
4,987 | 9,975 | 74.97 | 04/04/2026 | 2,224 | 213,571 | — | — | |||||||||||||||||||||
04/06/2018
|
6,920 | 3,461 | 85.31 | 04/05/2025 | 1,173 | 112,643 | — | — | |||||||||||||||||||||
04/07/2017
|
9,127 | — | 72.91 | 04/06/2024 | 515 | 49,455 | — | — | |||||||||||||||||||||
Mr. LaRouche | 12/11/2020 | — | — | — | 2,509 | 240,939 | — | — | |||||||||||||||||||||
04/03/2020 | — | 10,826 | 73.77 | 04/02/2027 | 3,896 | 374,133 | 3,949 | 379,193 | |||||||||||||||||||||
05/22/2019 | — | — | — | 1,168 | 112,180 | 2,234 | 214,509 | ||||||||||||||||||||||
04/05/2019 | — | — | — | 4,448 | 427,141 | — | — |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 42
|
EXECUTIVE COMPENSATION |
Option awards
|
Stock awards
|
|||||||||||||
Name
|
Number of shares
acquired on exercise
(#) |
Value realized
on exercise
($) (1) |
Number of shares
acquired on vesting
(#) (2) |
Value realized
on vesting
($) (1) |
||||||||||
Ms. Keene
|
15,459 | 893,221 | 19,338 | 1,667,939 | ||||||||||
Mr. Mathis | 16,732 | 348,862 | 9,003 | 795,565 | ||||||||||
Mr. Genter | 4,702 | 206,371 | 10,376 | 817,651 | ||||||||||
Mr. Mahon | 13,082 | 611,191 | 7,156 | 622,149 | ||||||||||
Mr. LaRouche | — | — | 2,222 | 165,183 |
43 | saic.com
|
EXECUTIVE COMPENSATION |
Name
(1)
|
Plan |
Executive
contributions
in fiscal 2021
($) (2) |
Aggregate
earnings in
fiscal 2021
($) (3) |
Aggregate
withdrawals/ distributions in fiscal 2021 |
Aggregate
balance at fiscal year-end ($) (4) |
||||||||||||
Mr. Genter |
Excess Plan
|
— | 2,157 | — | 18,585 | ||||||||||||
Deferred Compensation Plan
|
923 | 14,323 | — | 79,853 | |||||||||||||
Mr. Mahon |
Deferred Compensation Plan
|
105,829 | 334,767 | — | 1,673,641 | ||||||||||||
Mr. LaRouche |
Deferred Compensation Plan
|
270,864 | 104,084 | — | 464,604 |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 44
|
EXECUTIVE COMPENSATION |
45 | saic.com
|
EXECUTIVE COMPENSATION |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 46
|
EXECUTIVE COMPENSATION |
Name
|
Without Cause Termination
(not in connection with a Change in Control) ($) |
Without Cause or With
Good Reason Termination (in connection with a Change in Control) (1) ($) |
Retirement ($) |
Death ($)
|
Disability ($)
|
||||||||||||
Ms. Keene
|
|||||||||||||||||
Bonus
(2)
|
1,250,000 | 1,250,000 | 1,250,000 | — | — | ||||||||||||
Severance
(3)
|
4,005,917 | 7,417,500 | — | — | — | ||||||||||||
Medical coverage continuation
(4)
|
— | — | — | — | — | ||||||||||||
Outplacement services
(5)
|
25,000 | 25,000 | — | — | — | ||||||||||||
Stock options
(6)
|
2,240,466 | 2,240,466 | 2,240,466 | 2,240,466 | 2,240,466 | ||||||||||||
Restricted stock units
(7)
|
2,655,778 | 2,655,778 | 2,655,778 | 2,655,778 | 2,655,778 | ||||||||||||
Performance shares
(8)
|
(10)
|
2,945,680 |
(10)
|
2,945,680 |
(11)
|
||||||||||||
Applicable scale back
(9)
|
— | — | — | — | — | ||||||||||||
Total | 10,177,161 | 16,534,424 | 6,146,244 | 7,841,924 | 4,896,244 | ||||||||||||
Mr. Natarajan | |||||||||||||||||
Bonus
(2)
|
— | — | — | — | — | ||||||||||||
Severance
(3)
|
900,000 | 1,200,000 | — | — | — | ||||||||||||
Medical coverage continuation
(4)
|
49,306 | 65,741 | 49,306 | — | — | ||||||||||||
Outplacement services
(5)
|
25,000 | 25,000 | — | — | — | ||||||||||||
Stock options
(6)
|
— | — | — | — | — | ||||||||||||
Restricted stock units
(7)
|
507,423 | 507,423 | 507,423 | 507,423 | 507,423 | ||||||||||||
Performance shares
(8)
|
— | — | — | — | — | ||||||||||||
Applicable scale back
(9)
|
— | — | — | — | — | ||||||||||||
Total | 1,481,729 | 1,798,164 | 556,729 | 507,423 | 507,423 | ||||||||||||
Mr. Genter | |||||||||||||||||
Bonus
(2)
|
270,000 | 270,000 | 270,000 | — | — | ||||||||||||
Severance
(3)
|
1,365,065 | 2,160,000 | — | — | — | ||||||||||||
Medical coverage continuation
(4)
|
34,371 | 45,828 | 34,371 | — | — | ||||||||||||
Outplacement services
(5)
|
25,000 | 25,000 | — | — | — | ||||||||||||
Stock options
(6)
|
321,323 | 321,323 | 321,323 | 321,323 | 321,323 | ||||||||||||
Restricted stock units
(7)
|
1,027,260 | 1,027,260 | 1,027,260 | 1,027,260 | 1,027,260 | ||||||||||||
Performance shares
(8)
|
(10)
|
563,264 |
(10)
|
563,264 |
(11)
|
||||||||||||
Applicable scale back
(9)
|
— | — | — | — | — | ||||||||||||
Total | 3,043,019 | 4,412,675 | 1,652,954 | 1,911,847 | 1,348,583 | ||||||||||||
Mr. Mahon | |||||||||||||||||
Bonus
(2)
|
431,250 | 431,250 | 431,250 | — | — | ||||||||||||
Severance
(3)
|
1,502,765 | 2,100,000 | — | — | — | ||||||||||||
Medical coverage continuation
(4)
|
— | — | — | — | — | ||||||||||||
Outplacement services
(5)
|
25,000 | 25,000 | — | — | — | ||||||||||||
Stock options
(6)
|
568,499 | 568,499 | 568,499 | 568,499 | 568,499 | ||||||||||||
Restricted stock units
(7)
|
717,842 | 717,842 | 717,842 | 717,842 | 717,842 | ||||||||||||
Performance shares
(8
|
(10)
|
744,309 |
(10)
|
744,309 |
(11)
|
||||||||||||
Applicable scale back
(9)
|
— | — | — | — | — | ||||||||||||
Total | 3,245,356 | 4,586,900 | 1,717,591 | 2,030,650 | 1,286,341 | ||||||||||||
Mr. LaRouche | |||||||||||||||||
Bonus
(2)
|
240,000 | 240,000 | 240,000 | — | — | ||||||||||||
Severance
(3)
|
1,075,524 | 1,710,000 | — | — | — | ||||||||||||
Medical coverage continuation
(4)
|
39,333 | 52,444 | 39,333 | — | — | ||||||||||||
Outplacement services
(5)
|
25,000 | 25,000 | — | — | — | ||||||||||||
Stock options
(6)
|
240,987 | 240,987 | 240,987 | 240,987 | 240,987 | ||||||||||||
Restricted stock units
(7)
|
926,531 | 926,531 | 926,531 | 926,531 | 926,531 | ||||||||||||
Performance shares
(8)
|
(10)
|
445,143 |
(10)
|
445,143 |
(11)
|
||||||||||||
Applicable scale back
(9)
|
— | — | — | — | — | ||||||||||||
Total | 2,547,375 | 3,640,105 | 1,446,851 | 1,612,661 | 1,167,518 |
47 | saic.com
|
EXECUTIVE COMPENSATION |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 48
|
EXECUTIVE COMPENSATION |
49 | saic.com
|
PROPOSAL 3 - RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 50
|
AUDIT MATTERS |
51 | saic.com
|
AUDIT MATTERS |
January 29, 2021 | January 31, 2020 | |||||||
Audit Fees
(1)
|
$ | 5,200,000 | $ | 5,000,000 | ||||
Audit-Related Fees
(2)
|
$ | — | $ | 931,139 | ||||
Tax Fees
(3)
|
$ | 23,068 | $ | 115,739 | ||||
All Other Fees
(4)
|
$ | — | $ | 581,493 | ||||
Total Fees
|
$ | 5,223,068 | $ | 6,628,371 |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 52
|
OTHER INFORMATION |
Name and address of beneficial owner
|
Amount and nature of beneficial ownership | Percent of class | ||||||
Wellington Management Group LLP
(1)
|
5,954,533 | 10.3% | ||||||
c/o Wellington Management Company LLP 280 Congress Street
Boston, MA 02210
|
||||||||
The Vanguard Group
(2)
|
5,228,737 | 9.0% | ||||||
100 Vanguard Blvd.
Malvern, PA 19355
|
||||||||
BlackRock, Inc.
(3)
|
4,874,772 | 8.4% | ||||||
55 East 52nd Street
New York, NY 10055
|
||||||||
Boston Partners
(4)
|
4,100,985 | 7.1% | ||||||
One Beacon Street, 30th Floor
Boston, MA 02108
|
53 | saic.com
|
OTHER INFORMATION |
Beneficial Owner
|
Common stock
(1)
|
Stock units
(2)
|
Options and RSUs
(3)
|
Total shares beneficially owned | ||||||||||
Non-Employee Directors | ||||||||||||||
Robert A. Bedingfield
|
30,406 | 2,839 | 19,215 | 52,460 | ||||||||||
Carol A. Goode | 899 | — | 3,740 | 4,639 | ||||||||||
Garth N. Graham | — | — | — | — | ||||||||||
John J. Hamre | 14,321 | — | 10,185 | 24,506 | ||||||||||
Yvette M. Kanouff | 2,399 | — | 3,740 | 6,139 | ||||||||||
Timothy J. Mayopoulos | 5,664 | — | 19,215 | 24,879 | ||||||||||
Katharina G. McFarland | 1,932 | — | 6,047 | 7,979 | ||||||||||
Donna S. Morea | 15,874 | — | 28,229 | 44,103 | ||||||||||
Steven R. Shane | 23,429 | — | 19,215 | 42,644 | ||||||||||
Named Executive Officers | ||||||||||||||
Nazzic S. Keene | 73,556 | — | 158,677 | 232,233 | ||||||||||
Prabu Natarajan | 3,000 | — | — | 3,000 | ||||||||||
Charles A. Mathis
(4)
|
12,512 | — | 32,131 | 44,643 | ||||||||||
Robert S. Genter | 13,186 | — | 5,497 | 18,683 | ||||||||||
Steven G. Mahon | 19,321 | — | 34,808 | 54,129 | ||||||||||
Michael W. LaRouche | 4,015 | — | 3,608 | 7,623 | ||||||||||
All directors and executive officers as a group (15 persons) | 220,514 | 2,839 | 344,307 | 567,660 |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 54
|
OTHER INFORMATION |
55 | saic.com
|
APPENDIX TO PROXY STATEMENT |
Year Ended
|
|||||||||||
January 29, 2021
|
January 31, 2020
|
February 1,2019
|
|||||||||
(in millions) | |||||||||||
Net income | $211 | $229 | $137 | ||||||||
Interest expense and loss on sale of receivables | 124 | 90 | 53 | ||||||||
Interest income
|
(1) | (4) | (3) | ||||||||
Provision for income taxes | 60 | 57 | 33 | ||||||||
Depreciation and amortization
|
179 | 131 | 47 | ||||||||
EBITDA
(1)
|
$573 | $503 | $267 | ||||||||
EBITDA as a percentage of revenues | 8.1 | % | 7.9 | % | 5.7 | % | |||||
Acquisition and integration costs
|
54 | 48 | 86 | ||||||||
Restructuring costs | 4 | — | — | ||||||||
Depreciation included in acquisition and integration costs | (1) | (5) | — | ||||||||
Recovery of acquisition and integration costs and restructuring costs
(2)
|
(3) | (8) | — | ||||||||
Adjusted EBITDA
(1)
|
$627 | $538 | $353 | ||||||||
Adjusted EBITDA as a percentage of revenues
|
8.9 | % | 8.4 | % | 7.6 | % |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 56
|
APPENDIX TO PROXY STATEMENT |
Year Ended
|
|||||||||||
January 29, 2021
|
January 31, 2020
|
February 1,2019
|
|||||||||
(in millions) | |||||||||||
Performance Share Plan Adjusted Performance Measures | |||||||||||
Net income | $211 | $229 | $137 | ||||||||
Interest expense and loss on sale of receivables | 124 | 90 | 53 | ||||||||
Interest income | (1) | (4) | (3) | ||||||||
Provision for income taxes | 60 | 57 | 33 | ||||||||
Depreciation and amortization | 179 | 131 | 47 | ||||||||
EBITDA
(1)
|
$573 | $503 | $267 | ||||||||
EBITDA as a percentage of revenues | 8.1 | % | 7.9 | % | 5.7 | % | |||||
Acquisition and integration costs | 52 | 35 | 86 | ||||||||
Restructuring impacts | 2 | — | — | ||||||||
Performance share plan adjusted EBITDA | $627 | $538 | $353 | ||||||||
Performance share plan adjusted EBITDA as a percentage of revenues | 8.9 | % | 8.4 | % | 7.6 | % | |||||
Cash flows provided by operating activities | $755 | $458 | $184 | ||||||||
Excess tax benefits on stock based compensation | 3 | (4) | (9) | ||||||||
Cash paid for acquisition and integration costs | 32 | 18 | 59 | ||||||||
Restructuring impacts | (2) | — | — | ||||||||
Platform integration program working capital changes | 17 | 17 | 7 | ||||||||
Performance share plan adjusted operating cash flow | $805 | $489 | $241 | ||||||||
Short-Term Incentive Adjusted Performance Measures | |||||||||||
Revenue | $7,056 | $6,379 | $4,659 | ||||||||
Engility revenue | — | — | (98) | ||||||||
Government shutdown impact | — | — | 24 | ||||||||
COVID-19 impact | 262 | — | — | ||||||||
STI adjusted revenue | $7,318 | $6,379 | $4,585 | ||||||||
Net income
(2)
|
$211 | $229 | $156 | ||||||||
Interest expense and loss on sale of receivables | 124 | 90 | 53 | ||||||||
Interest income | (1) | (4) | (3) | ||||||||
Provision for income taxes
(2)
|
60 | 57 | 41 | ||||||||
Depreciation and amortization
(2)
|
179 | 131 | 43 | ||||||||
EBITDA
(1)
|
$573 | $503 | $290 | ||||||||
EBITDA as a percentage of revenues | 8.1 | % | 7.9 | % | 6.2 | % | |||||
Acquisition and integration costs | 52 | 35 | 54 | ||||||||
Restructuring impacts | 2 | — | — | ||||||||
COVID-19 impact | 16 | — | — | ||||||||
Impact of government shutdown | — | — | 3 | ||||||||
STI adjusted EBITDA | $643 | $538 | $347 | ||||||||
Cash flows provided by operating activities
(3)
|
$755 | $458 | $215 | ||||||||
Cash paid for acquisition and integration costs | — | — | 35 | ||||||||
Impact from government shutdown | — | — | 21 | ||||||||
Excess tax benefits on stock based compensation | 3 | (4) | (9) | ||||||||
Impact from sale of receivables under Master Accounts Receivable Purchase Agreement | (185) | — | — | ||||||||
COVID-19 impact | (73) | — | — | ||||||||
Restructuring impacts | (2) | — | — | ||||||||
STI adjusted operating cash flow | $498 | $454 | $262 |
57 | saic.com
|
APPENDIX TO PROXY STATEMENT |
Science Applications International Corporation | ||||||||
2021 Proxy Statement | 58
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
No Customers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|